{
    "nct_id": "NCT04132817",
    "official_title": "A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HER2 Negative Advanced Breast Cancer",
    "inclusion_criteria": "* Histological and cytological confirmation of adenocarcinoma of the breast\n* Documented HER2 negative and estrogen receptor (ER) positive status of primary or metastatic tumor tissue using the most recently assessed tumor specimen, according to the local laboratory parameters\n* ER negativity is defined as < 1% of tumor cells expressing hormonal receptors via IHC analysis\n* At least one measurable lesion, as per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1] that can be accurately assessed at baseline and is suitable for repeated assessment by computed tomography (CT) or magnetic resonance imaging (MRI)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Women and Men must agree to follow specific methods of contraception, if applicable, while participating in the trial\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Allergy or hypersensitivity to any study drugs or their excipients\n* Any other sound medical, psychiatric and/or social reason as determined by the investigator\n* Active, known, or suspected autoimmune disease or immune-related diseases\n* History of unstable or deteriorating cardiac disease within the previous 12 months prior to screening\n* Prior therapy with anti-programmed death 1 (PD-1), anti-programmed death-ligand 1 (PD-L1) or anti-Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) class antibody\n* Any major surgery within 4 weeks of the first dose of study treatment\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com"
}